Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
Theriva Biologics, Inc., a Nevada corporation, filed this Current Report on Form 8-K on March 6, 2025. The filing serves to announce the issuance of a press release containing financial information for the fiscal year ended December 31, 2024. The company's common stock trades on the NYSE American under the symbol TOVX.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document explicitly states that the financial data for the fiscal year ended December 31, 2024, is contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the text of this 8-K.
Material Changes
No material changes versus prior periods are detailed in the text of this filing. The report functions solely as a notification of the release of annual financial results.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information in Item 2.02 and the attached press release shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, and it shall not be incorporated by reference into any other SEC filings by the Company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 6, 2025) for specific revenue, net income, and cash position figures for the fiscal year ended December 31, 2024.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the attached press release.
- Check for any forward-looking statements or guidance provided in the press release that are not included in this 8-K summary.